Medacta Group (SWX:MOVE) - Aandelenkoers, Nieuws & Analyse

MOVE Overzicht aandelen

Medacta Group SA ontwikkelt, produceert en distribueert orthopedische en neurochirurgische medische hulpmiddelen in Europa, Noord-Amerika, Azië-Pacific en internationaal.

Over het bedrijf

MOVE fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	3/6
Prestaties in het verleden	3/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 18.84% per jaar groeien

De winst groeide het afgelopen jaar met 13%

Analisten zijn het erover eens dat de aandelenkoers met 22.9% zal stijgen

Risicoanalyse

Heeft een hoog schuldenniveau

Medacta Group SA Concurrenten

Medartis Holding

SWX:MED

CHF 763.2m

Metall Zug

SWX:METN

CHF 544.5m

Straumann Holding

SWX:STMN

CHF 18.5b

Sonova Holding

SWX:SOON

CHF 19.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Medacta Group
Historische aandelenkoersen
Huidige aandelenkoers	CHF 113.60
52 Week Hoogtepunt	CHF 135.00
52 Week Laag	CHF 107.80
Bèta	1.14
11 maand verandering	-8.83%
3 maanden verandering	-5.33%
1 Jaar Verandering	0.35%
33 jaar verandering	-28.91%
5 jaar verandering	38.54%
Verandering sinds IPO	18.21%

Recent nieuws en updates

Is Medacta Group (VTX:MOVE) A Risky Investment?

Oct 14

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

Sep 06

Recent updates

Is Medacta Group (VTX:MOVE) A Risky Investment?

Oct 14

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

Sep 06

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Aug 21

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Aug 06

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Jun 20

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Apr 17

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Mar 29

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Feb 22

Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Feb 07

Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Dec 18

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Dec 04

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Nov 15

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Oct 30

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Oct 17

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Sep 29

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Aug 11

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Jul 27

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

Jul 03

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Apr 28

Is Medacta Group (VTX:MOVE) A Risky Investment?

Apr 08

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dec 25

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Dec 09

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Nov 09

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

Sep 16

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Aug 20

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Jul 02

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

May 28

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

May 12

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Mar 31

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Mar 17

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Feb 07

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Dec 10

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Nov 05

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Sep 30

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Aug 26

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Jul 20

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

May 19

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Apr 05

What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Mar 02

Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

Feb 02

The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Jan 12

Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture

Dec 21

Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?

Dec 03

Rendement voor aandeelhouders

	MOVE	CH Medical Equipment	CH Markt
7D	-0.5%	-2.6%	-1.7%
1Y	0.4%	19.4%	11.0%

Rendement versus industrie: MOVE presteerde slechter dan de Swiss Medical Equipment -sector, die het afgelopen jaar een rendement van 19.4 % opleverde.

Rendement versus markt: MOVE presteerde slechter dan Swiss Market, dat het afgelopen jaar een rendement van 11 % opleverde.

Prijsvolatiliteit

Is MOVE's price volatile compared to industry and market?
MOVE volatility
MOVE Average Weekly Movement	3.8%
Medical Equipment Industry Average Movement	3.9%
Market Average Movement	3.2%
10% most volatile stocks in CH Market	7.1%
10% least volatile stocks in CH Market	1.6%

Stabiele aandelenkoers: MOVE heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van MOVE is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1958	1,826	Francesco Siccardi	www.medacta.com

Medacta Group SA ontwikkelt, produceert en distribueert orthopedische en neurochirurgische medische hulpmiddelen in Europa, Noord-Amerika, Azië-Pacific en internationaal. Het bedrijf biedt gepersonaliseerde 3D-planningshulpmiddelen voor gebruik bij heup-, knie-, schouder-, gewrichtsvervangings-, sportgeneeskunde- en wervelkolomprocedures. Medacta Group SA werd opgericht in 1958 en het hoofdkantoor is gevestigd in Castel San Pietro, Zwitserland.

Medacta Group SA Samenvatting

Hoe verhouden de winst en inkomsten van Medacta Group zich tot de beurswaarde?
MOVE fundamentele statistieken
Marktkapitalisatie	CHF 2.27b
Inkomsten(TTM)	CHF 53.03m
Inkomsten(TTM)	CHF 513.50m

42.7x

Koers/Winstverhouding

4.4x

P/S-verhouding

Is MOVE overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MOVE resultatenrekening (TTM)
Inkomsten	€544.29m
Kosten van inkomsten	€174.57m
Brutowinst	€369.72m
Overige uitgaven	€313.51m
Inkomsten	€56.21m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	2.82
Brutomarge	67.93%
Nettowinstmarge	10.33%
Schuld/Eigen Vermogen Verhouding	54.1%

Hoe presteerde MOVE op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.5%

Huidig dividendrendement

21%

Uitbetalingsratio

MOVE Overzicht aandelen

Beloningen

Risicoanalyse

Medacta Group SA Concurrenten

SWX:MED

CHF 763.2m

SWX:METN

CHF 544.5m

SWX:STMN

CHF 18.5b

SWX:SOON

CHF 19.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Is Medacta Group (VTX:MOVE) A Risky Investment?

First half 2024 earnings released: EPS: €1.91 (vs €1.46 in 1H 2023)

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Recent updates

Is Medacta Group (VTX:MOVE) A Risky Investment?

First half 2024 earnings released: EPS: €1.91 (vs €1.46 in 1H 2023)

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Now 20% undervalued after recent price drop

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dividend of CHF0.55 announced

Full year 2023 earnings: EPS and revenues miss analyst expectations

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Insufficient new directors

Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Medacta Group SA to Report Q4, 2023 Results on Feb 02, 2024

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

First half 2023 earnings released: EPS: €1.46 (vs €1.28 in 1H 2022)

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Upcoming dividend of CHF0.54 per share at 0.5% yield

Is Medacta Group (VTX:MOVE) A Risky Investment?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Medacta Group SA to Report Fiscal Year 2022 Results on Feb 03, 2023

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Medacta Group SA to Report Q2, 2023 Results on Sep 22, 2023

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

First half 2022 earnings released: EPS: €1.28 (vs €1.49 in 1H 2021)

Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Medacta Group SA Provides Revenue Guidance for the Year 2022

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

Medacta Group SA Approves Distribution

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Consensus forecasts updated

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Full year 2021 earnings: EPS misses analyst expectations

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Medacta Launches 360° (Anterior and Posterior) Cervical Platform, Highlighting MySpine Cervical, a Further Enhancement to the MySolutions Personalized Ecosystem

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS €1.49 (vs €0.48 in 1H 2020)

Medacta Group SA Confirms Revenue Guidance for the Year 2021

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Medacta Announces Successful Completion of First Reverse Shoulder Arthroplasties Using NextAR Augmented Reality Surgical Platform

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?